Yazan Abdullah
Internal Medicine · Newport Beach, CANPI 1194110676
Payments from drug & device makers
Across 753 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Viiv Healthcare Company$3K
- Merck$1K
- Johnson & Johnson$929
- EMD Serono, Inc.$587
- AbbVie$487
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$1361%
- Food & beverage$13,04798%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 335 | $5,232 |
| Viiv Healthcare Company | 142 | $2,707 |
| Merck | 60 | $1,259 |
| Johnson & Johnson(2 entities) | 53 | $929 |
| EMD Serono, Inc. | 29 | $587 |
| AbbVie(2 entities) | 29 | $487 |
| Amgen | 15 | $364 |
| Napo Pharmaceuticals Inc | 15 | $269 |
| Astellas Pharma US Inc | 8 | $243 |
| Eisai Inc. | 12 | $184 |
| Amarin Pharma, Inc. | 8 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $152 |
| Paratek Pharmaceuticals, Inc. | 5 | $117 |
| Melinta Therapeutics, LLC | 5 | $87 |
| Vyera Pharmaceuticals, LLC | 4 | $76 |
| Antares Pharma, Inc. | 4 | $66 |
| Theratechnologies Inc. | 4 | $64 |
| Lilly USA, LLC | 3 | $60 |
| Philips North America LLC | 3 | $55 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $42 |
| Nabriva Therapeutics, PLC | 2 | $38 |
| Tactile Systems Technology Inc | 2 | $30 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
How this compares
$13,307 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JulucaDolutegravir/Rilpivirine | 17 | $88,587 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $58,929 |
| MounjaroTirzepatide | 22 | $21,481 |
| Metformin Hcl ErMetformin Hcl | 23 | $332 |
| Rosuvastatin Calcium | 22 | $326 |
| Benazepril Hcl | 24 | $287 |
| Finasteride | 17 | $201 |
| Allopurinol | 13 | $178 |
| Amlodipine Besylate | 35 | $170 |
| Atorvastatin Calcium | 24 | $163 |
| Duloxetine Hcl | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca | $2,707 | $88,58717 claims |
| GileadBiktarvy | $5,232 | $58,92915 claims |
| Lilly USA, LLCMounjaro | $60 | $21,48122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Newport Beach
- Ryan KleinNewport Beach$5M
- Tung NgoNewport Beach$4.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.